The University of Notre Dame's Institute for Health Research is now conducting its first clinical trials in collaboration with MGC Pharmaceuticals. For studies, MGC will deliver a cannabis-based drug called CogniCann.
This is an oral spray containing a proprietary blend of THC, CBD, and other cannabinoids. MGC Pharmaceuticals's CBD-THC Ratio has been specifically developed to treat Alzheimer's symptoms and dementia.
"We are delighted to be working with MGC r to test this new approach to improving the quality of life of Australians currently suffering from this disease that cannot currently be cured," said Jim Codde, director of the Institute for Health Research, according to a media report.
Planning clinical trials with a cannabis-based drug
There are very few clinical trials on cannabis-based drugs. At the end of August, the Human Research Ethics Committee (HREC) of the University of Notre Dame, Western Australia (UNDA) gave scientists from the Institute for Health Research the green light to conduct the first clinical trials.
In addition, HREC approval was given after the completion of the ethics review required by the Australian Ethics Guide for Human Research to ensure the well-being of the patients included in the study. According to the director of the Institute for Health Research, prof. Jim Codde, the study's planning was very detailed and time-consuming, bringing together medical professionals, senior caregivers and industry stakeholders.
Conducting a drug study
The first clinical trial will include 50 subjects. To qualify, participants must be over 65 years of age. In addition, they must suffer from mild dementia or Alzheimer's. Another requirement is that they live in a recognized elderly care facility.
Subsequently, the researchers of the next 16-week, randomized, double-blind, placebo-controlled crossover trial will test the efficacy of the cannabis-based drug in the coming months.
The results of upcoming studies could be transformative not only for Australia but for the rest of the world. Getting rid of dementia and Alzheimer's patients from the anxiety and psychotic symptoms associated with the disease would not only improve the quality of life for patients but also relatives and caregivers.
Other interesting articles:
Alzheimer's disease and cannabis as medicine
Alzheimer: More research with medicinal cannabis
Alzheimer & # 39; s: a new study with cannabis drugs
Note: In this article, we report on prescription CBD or even cannabidiol. This article makes no suggestions for possible purposes. The benefits are left to pharmacists.